Library — CHDR

Search

Filter

Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery.

Prins S, Borghans L, de Kam ML, Groeneveld GJ, van Gerven J

Journal of the neurological sciences, 2023 Jun

View publication
Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI.

Leijenaar JF, Ingala S, Sudre CH, Mutsaerts HM, Leeuwis AE, van der Flier WM, Scheltens P, Weinstein HC, Barkhof F, van Gerven J, Groeneveld GJ, Prins ND

Cerebral circulation - cognition and behavior, 2023 May

View publication
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs.

Ferreira GS, Dijkstra FM, Veening-Griffioen DH, Boon WPC, Schellekens H, Moors EHM, van Meer PJK, Stuurman FE, van Gerven JMA

Translational psychiatry, 2023 Mar; 13(1):74

View publication
Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder

A. Safai Pour a b 1, S.J.M. van der Aalst a 1, I.J. Brouwer a, E.J. Giltay a, G.E. Jacobs a b, N.J.A. van der Wee a, A.M. van Hemert a, M.S. van Noorden

Journal of Affective Disorders Reports Volume 10, December 2022, 100400, 2022 Dec

View publication
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool.

Kwee CM, van Gerven JM, Bongaerts FL, Cath DC, Jacobs G, Baas JM, Groenink L

Journal of psychopharmacology (Oxford, England), 2022 Dec; 36(12):1299-1314

View publication
White Blood Cell and Platelet Counts Are Not Suitable as Biomarkers in the Differential Diagnostics of Dementia.

Schröder S, Heck J, Groh A, Frieling H, Bleich S, Kahl KG, Bosch JJ, Krichevsky B, Schulze-Westhoff M

Brain sciences, 2022 Oct

View publication
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers.

Dijkstra F, O'Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, Zuiker R, van Gerven J, Jacobs G

Translational psychiatry, 2022 Sep; 12(1):408

View publication
Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder

A.Safai Pour, S.J.M.van der Aalst, I.J.Brouwer, E.J.Giltay, G.E.Jacobs, N.J.A.van der Wee, A.M.van Hemert, M.S.van Noorden

Journal of Affective Disorders Reports, 2022 Aug

View publication
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

Dijkstra FM, Zuiker RGJA, Siebenga PS, Leigh-Pemberton RA, Sun L, Manthis JD, de Kam ML, Lin R, von Moltke LL, Rezendes D, van Gerven JMA

British journal of clinical pharmacology, 2022 Jun; 88(6):2909-2925

View publication

«
1
2
»